OncoCyte Corporation (OCX)
| Bid | 2.75 |
| Market Cap | 80.65M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -4.66 |
| PE Ratio (ttm) | -0.61 |
| Forward PE | -1.17 |
| Analyst | Buy |
| Ask | 3.02 |
| Volume | 42,019 |
| Avg. Volume (20D) | 84,373 |
| Open | 2.91 |
| Previous Close | 2.92 |
| Day's Range | 2.73 - 2.98 |
| 52-Week Range | 1.92 - 4.75 |
| Beta | 0.98 |
About OCX
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support...
Analyst Forecast
According to 4 analyst ratings, the average rating for OCX stock is "Buy." The 12-month stock price forecast is $4.62, which is an increase of 63.83% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
2 weeks ago · prismmediawire.com
Oncocyte to Release Fourth Quarter 2024 Results on March 24, 2025IRVINE, Calif., March 18, 2025 – PRISM MediaWire – Oncocyte Corp. (Nasdaq: OCX), a pioneering diagnostics technology company, today announced that it will report fourth quarter 2024 financial results ...
2 months ago · prismmediawire.com
Oncocyte Appoints Dr. Paul Billings as Consulting Chief Medical OfficerIrvine, Calif., Jan. 8, 2025 – PRISM MediaWire – Oncocyte Corp. (NASDAQ: OCX), a diagnostics technology company, announces the appointment of Dr. Paul Billings as the company's Consulting Chief Medica...
